{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T19:11:52Z","timestamp":1774293112606,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T00:00:00Z","timestamp":1469145600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2017,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Primary nodal marginal zone lymphoma (NMZL) is a rare disease. There is no current consensus on how to treat it. The bendamustine plus rituximab (BR) regimen is effective for the treatment of follicular and other indolent lymphomas, but its efficacy in NMZL is not known. We analyzed the outcome of 14 patients diagnosed with NMZL (median age 67\u00a0years) who were treated with 375\u00a0mg\/m<jats:sup>2<\/jats:sup> of rituximab on day 1 and 90\u00a0mg\/m<jats:sup>2<\/jats:sup> of bendamustine on days 1 and 2. The overall and complete response rates were 93% and 71%, respectively. Major toxicity (grade 3\/4 neutropenia) occurred in 5% of treatment courses. After a median follow\u2010up of 22\u00a0months (range: 18\u201055), the overall survival and the free survival rates were 100% and 93%, respectively. None of the patients showing a complete or partial response developed secondary myelodysplastic syndrome\/acute myeloid leukemia. Bendamustine plus rituximab was found to be an active and well\u2010tolerated regimen leading to the rapid control of disease.<\/jats:p>","DOI":"10.1002\/hon.2334","type":"journal-article","created":{"date-parts":[[2016,7,22]],"date-time":"2016-07-22T10:56:47Z","timestamp":1469185007000},"page":"536-541","source":"Crossref","is-referenced-by-count":13,"title":["The bendamustine plus rituximab regimen is active against primary nodal marginal zone B\u2010cell lymphoma"],"prefix":"10.1002","volume":"35","author":[{"given":"Kamel","family":"Laribi","sequence":"first","affiliation":[{"name":"Department of Hematology Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrien","family":"Tempescul","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut de Canc\u00e9ro\u2010H\u00e9matologie CHRU Brest  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Habib","family":"Ghnaya","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Denizon","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Besan\u00e7on","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreea","family":"Anghel","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Farhi","sequence":"additional","affiliation":[{"name":"Department of Hematology Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Truong","sequence":"additional","affiliation":[{"name":"Clinical Research Center Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Lemaire","sequence":"additional","affiliation":[{"name":"Laboratory of Biology and Hematology Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Poulain","sequence":"additional","affiliation":[{"name":"Service d'H\u00e9matologie\u2010Immunologie\u2010Cytog\u00e9n\u00e9tique Centre Hospitalier de Valenciennes  Valenciennes France"},{"name":"Laboratoire d'H\u00e9matologie, Centre de Biologie et Pathologie, CHRU de Lille  Lille France"},{"name":"INSERM UMR 1172, IRCL  Lille France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Delphine","family":"Bolle","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Centre Hospitalier du Mans  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Christophe","family":"Ianotto","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institut de Canc\u00e9ro\u2010H\u00e9matologie CHRU Brest  Brest France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alix","family":"Baugier de Materre","sequence":"additional","affiliation":[{"name":"Department of Medicine P\u00f4le Sant\u00e9 Sud  Le Mans France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,22]]},"reference":[{"issue":"2","key":"e_1_2_11_2_1","first-page":"310","article-title":"Monocytoid B\u2010cell lymphoma. A novel B\u2010cell neoplasm","volume":"124","author":"Sheibani K","year":"1986","journal-title":"Am J Pathol"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/87.1.121"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.1988.tb01953.x"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.5.1361.1361"},{"key":"e_1_2_11_6_1","first-page":"P161","volume-title":"Pathology & Genetics: Tumors of Haematopoietic and Lymphoid Tissues","author":"Isaacson PG","year":"2001"},{"key":"e_1_2_11_7_1","first-page":"P218","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Campo E","year":"2008"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2486"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2006.00345.x"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2005.02309.x"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl388"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000478-200306000-00006"},{"issue":"2","key":"e_1_2_11_13_1","first-page":"200","article-title":"Indolent lymphoplasmacytic and marginal zone B\u2010cell lymphomas: absence of both IRF4 and Ki 67 expression identifies a better prognosis subgroup","volume":"90","author":"Petit B","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-006-0160-y"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1052921.x"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-127-6-199709150-00002"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.1.299.299"},{"issue":"4","key":"e_1_2_11_18_1","first-page":"470","article-title":"Analysis of VH genes in marginal zone lymphoma reveals marked heterogeneity between splenic and nodal tumors and suggests the existence of clonal selection","volume":"90","author":"Traverse\u2010Glehen A","year":"2005","journal-title":"Haematologica"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.3.781"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.1.226"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"issue":"1","key":"e_1_2_11_22_1","first-page":"92","article-title":"Nodal marginal zone B\u2010cell lymphoma: a diagnostic and therapeutic dilemma","volume":"26","author":"Traverse\u2010Glehen A","year":"2012","journal-title":"Oncology"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.840888"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.1950"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-006-0014-9"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13078"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-436329"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2009.07677.x"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-011-1337-6"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27704"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24714"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26708"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61763-2"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-531327"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(14)00021-0"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06437.x"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a059292"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt507"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2334","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2334","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2334","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T16:57:43Z","timestamp":1695488263000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,22]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["10.1002\/hon.2334"],"URL":"https:\/\/doi.org\/10.1002\/hon.2334","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,22]]}}}